Author Archives: Steve Bryson PhD

axSpA patients stayed longest on TNF inhibitor golimumab: Study

Adults with axial spondyloarthritis (axSpA) remained on golimumab longer than any other TNF inhibitor, according to a real-world analysis of medical records. Although adalimumab (marketed as Humira and biosimilars) was the most commonly prescribed first- and second-line TNF inhibitor, patients stayed with golimumab (marketed…

Intensifying treatments for axSpA driven by MD’s perspective: Study

The decision to escalate treatment for people with highly active axial spondyloarthritis (axSpA) is mainly driven by the physician’s perspective on disease activity, a real-world study has revealed. Further research is needed to better understand these decisions and to optimize axSpA management, according to researchers in the study “…

Top-line data support Phase 3 trial of LNK01001 in hard-to-treat AS

An experimental therapy called LNK01001 can safely lower a measure of inflammation, pain, and stiffness in adults with active ankylosing spondylitis (AS) who were refractory or intolerant to non-steroidal anti-inflammatory drugs. These top-line data from a 12-week Phase 2 clinical trial support moving LNK01001 to a Phase 3 trial,…

Hip surgery complications increase hospital stays, costs for AS patients

Ankylosing spondylitis (AS) patients undergoing total hip replacement face longer hospital stays and higher related costs than other patients after the surgery, according to an analysis of hospital records. More complications, including anemia and infections, soon after surgery drove these increases in stays and admission-related costs, researchers noted. These…

New Inflammation Biomarker May Be Useful in AS, Study Suggests

The ratio of two blood proteins, fibrinogen and albumin, accurately measures inflammation severity with different types of spondyloarthritis (SpA), including ankylosing spondylitis (AS), a study showed. The accuracy of this biomarker closely matched those of standard inflammatory markers used in research and clinical practice. Further studies are needed to…

Long-standing Link Between AS and HLA-B27 Explained

Some immune T-cells that react to microbial proteins also target normal human proteins in people who carry HLA-B27 variants, the strongest genetic risk factor contributing to ankylosing spondylitis (AS), a study revealed. The shape of the protein fragments targeted by the immune T-cells, whether human or bacterial, was almost…

Bimekizumab Shows Symptom Improvements in Phase 3 Trials

One year of UCB Biopharm‘s investigational therapy bimekizumab, administered subcutaneously (under the skin) once every four weeks, resulted in sustained improvement in the signs and symptoms of axial spondyloarthritis (axSpA), according to late-breaking data from two BE MOBILE Phase 3 clinical trials. axSpA is a type of inflammatory…

Restarting Taltz After Withdrawal Reduces axSpA Activity: Trial Data

Almost all people with axial spondyloarthritis (axSpA) who had worsening disease severity after stopping Taltz (ixekizumab) saw improvements after restarting the therapy, according to data from a Phase 3 withdrawal study. The majority (71%) reached a state of disease remission after restarting treatment. These findings provide important information about…